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High quality, patient centred and
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Qiaoying Wang1, Kay Parkinson3, Timothy Barrett4 and Tarekegn Geberhiwot5*
Abstract
Background: Patients with rare and ultra-rare diseases make heavy demands on the resources of both health and
social services, but these resources are often used inefficiently due to delays in diagnosis, poor and fragmented
care. We analysed the national service for an ultra-rare disease, Alstrom syndrome, and compared the outcome and
cost of the service to the standard care.
Methods: Between the 9th and 26th of March 2014 we undertook a cross-sectional study of the UK Alstrom
syndrome patients and their carers. We developed a semi-structured questionnaire to assess our rare patient need,
quality of care and costs incurred to patients and their careers. In the UK all Alstrom syndrome patients are seen in
two centres, based in Birmingham, and we systematically evaluated the national service and compared the quality
and cost of care with patients’ previous standard of care.
Results: One quarter of genetically confirmed Alstrom syndrome UK patients were enrolled in this study. Patients
that have access to a highly specialised clinical service reported that their care is well organised, personalised,
holistic, and that they have a say in their care. All patients reported high level of satisfaction in their care. Patient
treatment compliance and clinic attendance was better in multidisciplinary clinic than the usual standard of NHS
care. Following a variable costing approach based on personnel and consumables’ cost, our valuation of the clinics
was just under £700/patient/annum compared to the standard care of £960/patient/annum. Real savings, however,
came in terms of patients’ quality of life. Furthermore there was found to have been a significant reduction in
frequency of clinic visits and ordering of investigations since the establishment of the national service.
Conclusions: Our study has shown that organised, multidisciplinary “one stop” clinics are patient centred and
individually tailored to the patient need with a better outcome and comparable cost compared with the current
standard of care for rare disease. Our proposed care model can be adapted to several other rare and ultra-rare
diseases.
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Background
Alstrom syndrome (AS) is an ultra- rare inherited
genetic disorder affecting less than one in a million
people globally. AS is characterised by progressive vis-
ual impairment usually present within the first year of
life; sensorineural hearing loss often in the first dec-
ade of life; and cardiomyopathy with progression to
heart failure either in infancy or in adolescence.
Obesity with all its metabolic consequences such as
diabetes, dyslipidaemia and hypertension develops in
early childhood. Additionally, a large proportion of
AS patients suffer from kidney and liver disease.
There is as yet no disease specific treatment available
and the disease usually progresses to death in child-
hood (from cardiac failure) or early adulthood (car-
diac or renal failure) where survival beyond the age
of 50 is rare [1]. These combinations of pathologies
mean that patients require appointments with mul-
tiple subspecialists, take many medications, and are
frequently hospitalised.
The current model of health care in Europe and beyond
is well designed to cater for patients with common condi-
tions. However, these care delivery models are not suited
for patients with complex multisystem diseases with
health needs that cross subspecialties. As with many rare
diseases, awareness of AS amongst the medical commu-
nity is very low and most physicians caring for these pa-
tients may only see one or two patients throughout their
career. The medical profession is therefore unfamiliar with
the condition, and has minimal specific training, resulting
in a feeling of unpreparedness to provide optimal care.
This unfamiliarity leads to numerous misdiagnoses, mis-
treatment and even harm to patients.
Most patients with rare diseases have complex multi-
system medical needs requiring patient-centred multidis-
ciplinary clinics. The lack of patient/disease tailored
health services has led to the development of patient
self-support groups in the rare disease community to
help navigate families through the existing health care
system [2]. In 2000, Alstrom Syndrome UK (ASUK) was
established by a handful of families, who then persuaded
their physicians to set up a multidisciplinary clinic
(MDC) in a hotel funded by the charity [3]. Five years
later, ASUK’s contribution to providing care to their
members was recognised by the UK department of
health and a national Alstrom service was established
for both children and adult patients. Ten years later, the
National Health Service (NHS) England highly specia-
lised Alstrom’ service is the only organised MDT service
for AS sufferers in the world and accepts patient refer-
rals from as far away as Australia.
The provision of personalised multidisciplinary care by
an expert centre has to be cost effective. In consequence,
in collaboration with the London School of Economics
we undertook a cost benefit analysis of the NHS England
Alstrom syndrome national service. This study aimed to
identify the costs and benefits of running a patient
centred highly specialised clinic for an ultra-rare disease
and share best practices.
Study background
Setting
In the UK, there are two nationally commissioned highly
specialised clinics for AS based in Birmingham; one is
specialised for children and the other for adults. Both
hospitals provide multidisciplinary team (MDT) annual
review clinics, each for respective age groups.
The patient support group ASUK is recognised by the
department of health as an equal partner and it receives
direct funding from NHS-England to provide support to
the patients and their families during their clinic visit.
These clinics have personalised shared care arrange-
ments with the local care providers.
The clinics occur every three months and last 2 and
half days as follows: Day one takes place in a local hotel
and days 2 and 3 are conducted in a hospital setting.
Day 1: Round table discussion and psychological support
The adult patients arrive at their hotel by mid-afternoon,
receive a detailed personalised schedule during their stay
in Birmingham and further explanation is given as re-
quired, and after a brief rest they are invited to attend a
round table meeting with the family support group and
the clinical team. The first part of the meeting is a group
discussion: meeting other patients and families, sharing
patients’ experiences, understanding what treatment
methods were particularly effective and which were not,
and how other families overcome challenges potentially
faced by an individual patient. Day 1 also includes asking
the patient’s view about the NHS-specialist clinics; what
is working for them, and what changes they would like
to see in the future. This round table patient led discus-
sion also consists of a discussion of progress in AS re-
search and new developments, and any future potential
benefit. The second part of the session consists of psy-
chological support to patients in a private room as re-
quired. Accommodation and hotel meeting rooms are all
organised and paid for by ASUK. The child and young
person patients arrive at their hotel by mid afternoon
the day before the clinic, have 24 h blood pressure mon-
itors fitted if required, and participate in an educational
event such as making healthy foods, in the parent kit-
chen area. At the same time, the transition coordinator,
dietician, paediatric specialist nurse and doctor are on
hand to meet families, answer any questions and allay
any anxieties. The following day there is psychological
support for families during the clinic, and a round table
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discussion by young people on what they would like
from the clinic.
Day 2: Investigations and clinics
Investigations typically consist of blood and urine tests;
cardiac magnetic resonance imaging; high resolution chest
computerised tomography; abdominal ultrasound; lung
function test; ECG; 24 h blood pressure monitoring; uro-
dynamic study; and other tests as deemed appropriate.
Many of these tests are individually tailored.
The consultations in day 2 include: Hearing test and
adjustment to their hearing aids; exercise and physio-
therapy; pharmacy review of patients’ medical treatment
and compliance; AS specialist nurse review and add-
itional psychological support.
Day 3: MDT clinics
Patients rotate between the various specialists in the
clinic as follows:
a. Metabolic- consists of metabolic physicians and
diabetic specialist nurses. The overall MDT clinics
are coordinated by the metabolic team.
b. Cardiology- consultant cardiologist and cardiac
technician. Echocardiogram in the clinic and review
of their clinical progress and optimisation of cardiac
treatment.
c. Respiratory
d. Dietetics
e. Ophthalmology
f. Bespoke clinics- urology, hepatology, dermatology,
ENT, gynaecology, genetics and others as required
At the end of the clinic there is an MDT meeting with
all specialist care givers to discuss individual patients and,
if required, make further changes to their management.
Following this MDT meeting if any of the patients’ care
plans change, those patients would be called in one more
time and changes would be discussed and agreed with the
individual patient.
Methods
Two separate research pieces were conducted to analyse
the effectiveness of the MDC, both from a qualitative
and a quantitative standpoint. This involved a survey of
all AS patients registered with ASUK in the UK, a cost
analysis of the clinical service providers, and a quality of
life analysis as follow:
Survey
Between the 9th and 26th of March 2014 we undertook a
cross-sectional study and enrolled 100 % of all AS patients
and carers in the UK with a 23 % response rate. Patients
and carers were invited for pre-interview discussions and
this formed the basis of the structured interviews. The
semi-structured interviews were designed to address the
socio-economic implications of living with, caring for, and
treating patients suffering from AS [5]. The interview
design was a semi-structured set up, which was built
around open and semi-open questions, providing freedom
to the respondent to focus on different subjects and com-
ment on the most relevant issues of their health care [4].
The interviews were conducted either on the telephone or
face to face lasting on average 35–60 min.
We undertook measures to improve the reliability
(providing consistent measures in comparable situations)
and validity (ensuring that answers correspond to the
questions that they were intended to measure) of the
questionnaires as follow:
a. Careful attention was paid to how the survey was
constructed: for example, the phrasing of questions
was rigorously analysed and refined; spacing of
questions and section headings was designed to
stimulate understanding and structure the survey to
be more effective and intuitive.
b. Data validation parameters were implemented into
the digital survey (in other words, if a question
required a numerical answer, only numeric inputs
were accepted) [6].
c. All respondents were asked identical sets of
questions.
d. Interviewers were trained to avoid potential biases
affecting responses. Interviewers were provided a
script to which they were expected to strictly adhere
to.
e. All questions needed to be answered in order to
progress through the survey.
f. Surveys were kept completely anonymous. This was
to ensure that all participants were willing to answer
questions as accurately as possible without fear or
favour.
In our data collection we took the following steps to
minimise bias as described by Fowler et al. [7]. To avoid
sample frame bias we set up our surveys so that the pa-
tient or their caregiver could complete it. For those who
were unable to complete the survey due to its format,
we offered the option of talking volunteers through the
survey and completing them on their behalf. Assistants
were briefed to ensure no bias was introduced during
this process. Given the low prevalence of the syndrome,
we attempted to reach out to all AS sufferers across the
UK to avoid human discretion in patient selection. Pa-
tient details were obtained from AS UK’s database based
on patients’ availability and willingness to participate in
this research project. In addition, the survey was set up
using an online digital form, which eliminated access
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problems relating to survey dissemination, completion
and collection. To ensure everyone was able to complete
the survey we provided support such as telephone assist-
ance to work through the survey with patients who were
unable to complete it due to varying sensory losses. We
also ensured the survey was compatible with screen
reader software such as JAWS, NVDA, ChromeVox, and
VoiceOver. We also sought advice from experts in the
field of dual sensory losses.
Cost analysis
To better understand the efficacy of the clinics we
undertook to determine whether the cost of their set
up and running is feasible for national health care pro-
viders. This achieved, direct comparisons between
MDT clinical care and standard practices could be
drawn. The costing approach can be described as fol-
lows. First, a detailed overview of all aspects of the
clinics was set up with the help of patient interviews,
as described above. In a second step, we conducted a
site visit and physician interviews to gain a more de-
tailed (and medical) picture of the exact treatments
involved, their layout in the hospital and the respect-
ive personnel involved in each practice. Third, we
spoke to a finance manager from both care providers
who were able to provide valuable insights into the
costs involved in care (the cost categories employed
by the NHS, and appropriate hourly rates for each ac-
tivity in the clinic).
Based on our initial interview findings, we therefore
formed three cost categories:
1. Variable direct personnel costs defined as the
hourly rates of specialist physicians (such as a
cardiologist), technicians (such as a cardiac
technician), nurses (for example for monitoring
purposes) and support personnel (for example
providing organisational assistance and helping
moving patients between clinics).
2. Consumables defined as all materials that might be
used in a treatment that are non-capital expenses,
and would mostly be used only once (such as ban-
dages). In the model, these were taken as a percent-
age of the personnel costs and adapted to the best of
our knowledge depending on the treatment type.
3. Capital expenses and overhead divided into two
buckets: first, there is the capital equipment to
consider that is used to perform the examinations. If
this equipment has a useful life of 5-10years, for ex-
ample, this cost could arguably be allocated to each
treatment. However, as there is no direct association
between the use of the equipment and their depreci-
ation, this cost was not assigned to the MDC. We
believe this is particularly fair as to the best of our
knowledge, no additional equipment had to be pur-
chased to run the MDC and all equipment was
already available and in use. The same logic applies
to overhead costs, such as rent. As no additional fa-
cilities had to be rented to run the clinics, this cost
is arguably fixed and does not need to be considered
in the model, which in theory should only investi-
gate the marginal cost of treatment.
The cost of the standard care was derived from the
interview based on the number and speciality of clinics
they had attended. We then used the NHS-national tariff
to calculate the annual clinics cost.
Quality of life analysis
We used an additional measure to assess patient quality
of life resulting from the use of MDC services. We mea-
sured this variable using the Health Utilities Index scales
(HUI) that uses the factors of vision, hearing, speech,
walking, dexterity, happiness, cognition, and pain in the
measure related to good health. This yielded a realistic
assessment of AS patient’s quality of life compared to
both healthy individuals and other patients suffering
from chronic life-limiting diseases.
Statistical analysis
Interview transcripts and field notes were thematically
analysed using a combination of inductive and de-
ductive coding. Descriptive analysis was performed
and a two-tailed p-value <0.05 was assumed as statis-
tically significant. Statistical analysis of the two-tailed
p-value test was performed using SPSS 17.0 software.
Results
Quantitative clinical valuation results
Based on the physician interviews we were able to identify
12 areas of treatment, which we bundled into 12 cost
centres. Each cost centre was assigned both its direct vari-
able personnel costs and the cost of consumables (if any).
As stated above, capital expenses and overhead were not
allocated.
AS shown in Fig. 1 the total cost for each MDT clinic
thereby amounts to GBP 4,138 for a total of 6 patients, or
approximately GBP 690 per annum per patient (assuming
single annual visits and 6 patient clinics). By far the largest
cost category in our model surprisingly turned out be
assistant personnel costs – i.e. for nurses involved in the
organisation and set up of the MDT clinics. Other major
cost drivers (defined as costs contributing more than 10 %
of total costs) included experts’ time in the fields of oph-
thalmology (18 %), endocrinology (14 %) and cardiology
(12 %). Nurse and dietician counselling in dietary advice,
diabetes and psychological treatment time turned out to
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be the least expensive elements of the MDT with only 2 %
contribution to total cost each.
The cost analysis of the MDT clinic hereby gives an
indicative estimate of the costs involved in the set-up,
running and treatments involved in the MDT clinic. As
pointed out in the data limitations section, though, much
deeper analysis of the respective services involved would
have to be conducted to make this figure more realistic.
Our cost assessment of the standard care based on
individual specialists clinic cost was estimated to
£960/patient/year as per 2014 National Health Service
tariff [8].
Qualitative patient related quality of life results
The quality of life analysis, as shown in Fig. 2, dem-
onstrates clearly that patients with AS have a worst
quality of life (0.5) of that of a healthy individual and
have a lower HUI scale than other common chronic
diseases including Rheumatoid arthritis or coronary
heart disease.
Patient satisfaction
Patient has shown a high level of satisfaction in their
care delivery, continuity and integration (data not
shown).
Discussion
From our experience, 21st century medical care is tai-
lored to common diseases with relatively high preva-
lence and has improved the general standard of health
care considerably. However, a process designed for
common diseases will require further adjustment to
cater for patients with rare and ultra-rare diseases. The
NHS in the UK has recognised the need for commis-
sioning highly specialised services separately with an
establishment of clinical expert centres ranging from 1
to 7 per disease or groups of disease sufferers. Many of
these highly specialised services are dedicated to pro-
viding care for rare and ultra-rare diseases. The AS
service in our centre is the largest centre for this dis-
ease in the world
 £-
 £1,000
 £2,000
 £3,000
 £4,000
MDTC Cost Drivers 
Fig. 1 Direct personnel cost of the national multidisciplinary clinics. All costs are in British pounds per clinic for six patients at a time
Major cost drivers
(>10 % of total cost)
Minor cost drivers
(<10 % of total cost)
▪ Cardiology (12 %)
▪ Ophthalmology (18 %)
▪ Endocrinology (14 %)
▪ Assisting personnel (26 %)
▪ Pre-MDT counselling (3 %)
▪ Genetics (9 %)
▪ Morning group discussion (3 %)
▪ Diabetes (2 %)
▪ Dietary advice (2 %)
▪ Physiotherapy (5 %)
▪ Psychology (2 %)
▪ Geriatrics (4 %)
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This research has shown that organised, patient centred,
multidisciplinary “one stop” clinics are more patient-
friendly with better outcomes than the current care model
where patients with rare diseases see several specialists at
different sites and at different dates. There is no published
data to support or refute this. Our study compared the
current one stop clinic with their previous standard of
care and the results showed a high level of patient satisfac-
tion in their MDT clinics and with several added benefits
to their care. We found that our model of patient-centre,
knowledge-based rare disease MDT clinics have improved
care for patients and knowledge to care givers as follow:
Patients
 High level of satisfaction with their care:
Satisfaction with AS care encompasses care
delivery, expectations, attitudes, and disease
management. Patients were highly satisfied with
communication, approach to addressing their
complex need and the time they were given to
spend with each specialists. Patients felt their
MDT clinic care givers are expert clinicians who
are familiar with their conditions. In recent years
it has become evident that the patient experience
of care is a valuable quality measure to improve
care processes [9]. Our study is in agreement
with previous evidence that showed team-based
care is better than usual care in improving patient
satisfaction [10].
 Continuity of care: AS specialist centres provide
support to local care givers. If and when
challenging health needs arise patients can be
referred back to their expert centre as per the
shared care pathway. It has been shown that
patient care improves considerably when there is
a shared care arrangement between local and
expert centres [11].
 Certainty: Patients no longer need to suffer from
conflicting information from health care providers
who are unfamiliar with patients’ disease
condition. Patient confidence in the health care
system is a prerequisite for patient engagement in
their chronic and progressive disease care. The
open led discussions in Birmingham concluded
that there was a high level of patient confidence
towards the MDT clinics. Evidence suggests
patient dissatisfaction leads to decreased
compliance and poor disease control [12].
 Time efficient: Only two days are required for the
MDC visit and 5 more days to see their local care
providers per year. The alternative is fragmented care,
entailing numerous days wasted seeing different
physicians and having numerous and repetitive
investigations.
 Education: MDT clinic play an important role as
a knowledge hub to patients and caregivers about
the rare disease and its management. In general,
there is a scarcity of information on rare diseases,
including the natural history of the disease. It is
therefore vital that patients and carers are well
informed. Evidence from other chronic diseases
[13] suggests the patient education empower
patients to self-manage and coordinate their care.
Fig. 2 Health related quality of life for Alstrom syndrome patients compared to other chronic diseases
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 Research: The MDTclinics offer the opportunity for
patients to participate in research to better understand
the natural history of the disease and ultimately
develop new types of therapy.
 Ownership: patients felt they own their service and
their voice is well heard in shaping their care
pathway. They also felt they are empowered to
make their own health choices.
Care-givers
 Acquired sufficient knowledge and experience to
manage a complex rare disease. When disease
prevalence is less than 1:1,000,000 it is obvious that
most specialist physicians may not have seen the
condition when they encounter patient with ultra-rare
disease and a single or two patients might be the only
patient they will see in their entire carrier. It is there-
fore bound to be a knowledge gap and lack of experi-
ence in managing rare patient’s complex need and
care-givers feel inadequate and ultimately impact on
the quality of care they provide. A recent global study
looking at Hepatitis C management identified poor
patient care was strongly associated with lack of
knowledge of treating Physician [14]
 Shared knowledge of experts by having several
specialists under one roof. Specialists learned from
each other and able to communicate effectively by
having pre and post clinic MDT meetings (rather
than email/letter or scheduled meetings).
 Patients attended all their clinic and test appointment.
It is well recognised that patient non-attendance
(DNAs) in chronic disease have an enormous impact
on the healthcare system in terms of cost and waiting
time, significantly adding to delays along the patient
pathway. Our patients 100 % clinic attendance allow
us for efficient running of clinics, increase productiv-
ity, reduce costs and improve care [15].
 Able to undertake research in the particular rare
disease and improve not only the care of our own
patient but the AS community at large [16–18].
Pooling all the UK and international patient allow us
to acquire sufficient number of patient to undertake
several large scale research initiatives in including
European patient registry [19].
Impact on patient life/society
The medical journey travelled by patients with a rare dis-
ease (and their families) from initial disease recognition or
onset of symptoms to a final diagnosis and treatment may
involve serial referrals to several specialists and a plethora
of often invasive and repetitive tests. This odyssey can be
long and not fully understood by medical professionals.
This has serious consequences for the health of patients
with delayed diagnosis and suboptimal therapy. The hidden
cost of treating and caring for patient with rare disease is
substantial. For example patients attending a dedicated
MDT clinic made fewer visits compared to the standard
care, reducing the cost related to their healthcare. In
addition, AS has huge burden on family, friends, health and
social service requiring disproportionately large resource
from tax payer. On the other hand, if patients are treated
optimally, he/she can therefore be a net contributor to the
national economy rather than beneficiaries.
Limitations and further analysis
Several limitations require attention. First, the overall sample
size is small. We reached out to all UK patients and were able
to recruit a quarter of the UK cohort. Second, comparable
data is scarce in rare and ultra-rare disease and unable to fully
evaluate our MDT service. One would hope this is the first of
many best practice sharing studies in rare and ultra-rare
disease care. Third, although the large bulk of the costing is
accurate (direct personnel costs) other costing (indirect costs/
follow-up costs locally/consumables) is based on national
tariffs and educated assumptions and may under-estimate
cost. This, however, will be the same pre and post MDT cost-
ing and hence direct comparison can still be made. Fourth,
the MDT clinic was designed as a clinical service rather than
for research and we were unable to capture fully clinical out-
come measures prior to MDT clinic (2006) and hence our
outcome measure was based on patient reported outcome.
Conclusion
Despite the limitations of the study we believe the model
of care we have outlined in this article provides a best
practice for ultra-rare disease care. It is patient led, indi-
vidually tailored to a complex need and at a cost that is
comparable to the standard care. In addition, the MDT
clinics have served as a referral centre for international pa-
tients and a nucleus in driving large-scale research in AS.
Finally, AS patients’ centred and personalised care can
serve as a paradigm for other rare and ultra-rare diseases.
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